Recently, carbon nanocomposites have garnered a lot of curiosity because of their distinctive characteristics and extensive variety of possible possibilities. Among all of these applications, the development of sensors with electrochemical properties based on carbon nanocomposites for use in biomedicine has shown as an area with potential. These sensors are suitable for an assortment of biomedical applications, such as prescribing medications, disease diagnostics, and biomarker detection. They have many benefits, including outstanding sensitivity, selectivity, and low limitations on detection. This comprehensive review aims to provide an in-depth analysis of the recent advancements in carbon nanocomposites-based electrochemical sensors for biomedical applications. The different types of carbon nanomaterials used in sensor fabrication, their synthesis methods, and the functionalization techniques employed to enhance their sensing properties have been discussed. Furthermore, we enumerate the numerous biological and biomedical uses of electrochemical sensors based on carbon nanocomposites, among them their employment in illness diagnosis, physiological parameter monitoring, and biomolecule detection. The challenges and prospects of these sensors in biomedical applications are also discussed. Overall, this review highlights the tremendous potential of carbon nanomaterial-based electrochemical sensors in revolutionizing biomedical research and clinical diagnostics.
In the last several decades, cardiovascular diseases (CVDs) have emerged as a major hazard to human life and health. Conventional formulations for the treatment of CVD are available, but they are far from ideal because of poor water solubility, limited biological activity, non-targeting, and drug resistance. With the advancement of nanotechnology, a novel drug delivery approach for the treatment of CVDs has emerged: nano-drug delivery systems (NDDSs). NDDSs have shown significant advantages in tackling the difficulties listed above. Cytotoxicity is a difficulty with the use of non-destructive DNA sequences. NDDS categories and targeted tactics were outlined, as well as current research advancements in the diagnosis and treatment of CVDs. It’s possible that gene therapy might be included into nano-carriers in the delivery of cardiovascular medications in the future. In addition, the evaluation addressed the drug’s safety.
This review discusses the significant progress made in the development of CNT/GO-based biosensors for disease biomarker detection. It highlights the specific applications of CNT/GO-based biosensors in the detection of various disease biomarkers, including cancer, cardiovascular diseases, infectious diseases, and neurodegenerative disorders. The superior performance of these biosensors, such as their high sensitivity, low detection limits, and real-time monitoring capabilities, makes them highly promising for early disease diagnosis. Moreover, the challenges and future directions in the field of CNT/GO-based biosensors are discussed, focusing on the need for standardization, scalability, and commercialization of these biosensing platforms. In conclusion, CNT/GO-based biosensors have demonstrated immense potential in the field of disease biomarker detection, offering a promising approach towards early diagnosis. Continued research and development in this area hold great promise for advancing personalized medicine and improving patient outcomes.
Introduction: the presence of anti-CCP is an important prognostic tool for rheumatoid arthritis (RA), but its relationship with the activity of the disease and functional capacity is still being investigated. Objectives: to study the relationship between anti-CCP and the indices of disease activity, functional capacity and structural damage, by means of conventional radiography (CR) and magnetic resonance imaging (MRI), in stabilized RA. Methods: cross-sectional study of RA patients with one to 10 years of disease. The participants were subjected to clinical evaluation with anti-CCP screening. Disease activity was assessed by means of the Clinical Disease Activity Index (CDAI) and functional capacity by means of the Health Assessment Questionnaire (HAQ). CR was analyzed by the Sharp van der Heijde index (SmvH) and MRI by the Rheumatoid Arthritis Magnetic Resonance Image Scoring System (RAMRIS). Results: 56 patients were evaluated, with median (IIq) of 55 (47.5–60.0) years, 50 (89.3%) were female among whom 37 (66.1%) were positive for anti-CCP. The median (IIq) of CDAI, HAQ, SmvH and RAMRIS were 14.75 (5.42–24.97), 1.06 (0.28–1.75), 2 (0–8) and 15 (7–35), respectively. There was no association between anti-CCP and CDAI, HAQ, SmvH and RAMRIS. Conclusion: our results did not establish the association of anti-CCP with the severity of the disease. So far, we cannot corroborate the anti-CCP as a prognostic tool in RA established.
Copyright © by EnPress Publisher. All rights reserved.